These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29763776)

  • 1. Dimethyl fumarate downregulates the immune response through the HCA
    von Glehn F; Dias-Carneiro RPC; Moraes AS; Farias AS; Silva VAPG; Oliveira FTM; Silva CEBG; de Carvalho F; Rahal E; Baecher-Allan C; Santos LMB
    Mult Scler Relat Disord; 2018 Jul; 23():46-50. PubMed ID: 29763776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response.
    Parodi B; Sanna A; Cedola A; Uccelli A; Kerlero de Rosbo N
    Front Immunol; 2021; 12():655212. PubMed ID: 34084164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis.
    Hosseini A; Masjedi A; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Anvari E; Jadidi-Niaragh F
    J Cell Physiol; 2019 Jul; 234(7):9943-9955. PubMed ID: 30536402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation.
    Wannick M; Assmann JC; Vielhauer JF; Offermanns S; Zillikens D; Sadik CD; Schwaninger M
    Front Immunol; 2018; 9():1890. PubMed ID: 30154797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells.
    Fiedler SE; Kerns AR; Tsang C; Tsang V; Bourdette D; Salinthone S
    Biochem Biophys Res Commun; 2016 Jun; 475(1):19-24. PubMed ID: 27157139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
    Chen H; Assmann JC; Krenz A; Rahman M; Grimm M; Karsten CM; Köhl J; Offermanns S; Wettschureck N; Schwaninger M
    J Clin Invest; 2014 May; 124(5):2188-92. PubMed ID: 24691444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies.
    Montes Diaz G; Hupperts R; Fraussen J; Somers V
    Autoimmun Rev; 2018 Dec; 17(12):1240-1250. PubMed ID: 30316988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.
    Diebold M; Sievers C; Bantug G; Sanderson N; Kappos L; Kuhle J; Lindberg RLP; Derfuss T
    J Autoimmun; 2018 Jan; 86():39-50. PubMed ID: 28958667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium.
    Breuer J; Herich S; Schneider-Hohendorf T; Chasan AI; Wettschureck N; Gross CC; Loser K; Zarbock A; Roth J; Klotz L; Wiendl H; Schwab N
    Mult Scler; 2018 Dec; 24(14):1871-1882. PubMed ID: 28984166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.
    Traub J; Traffehn S; Ochs J; Häusser-Kinzel S; Stephan S; Scannevin R; Brück W; Metz I; Weber MS
    Brain Pathol; 2019 Sep; 29(5):640-657. PubMed ID: 30706542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
    Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.
    Smith MD; Calabresi PA; Bhargava P
    Eur J Immunol; 2018 Feb; 48(2):380-383. PubMed ID: 29108094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
    Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
    Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages.
    Feingold KR; Moser A; Shigenaga JK; Grunfeld C
    J Lipid Res; 2014 Dec; 55(12):2501-8. PubMed ID: 25320346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases.
    Majkutewicz I
    Eur J Pharmacol; 2022 Jul; 926():175025. PubMed ID: 35569547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
    Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.
    Parodi B; Rossi S; Morando S; Cordano C; Bragoni A; Motta C; Usai C; Wipke BT; Scannevin RH; Mancardi GL; Centonze D; Kerlero de Rosbo N; Uccelli A
    Acta Neuropathol; 2015 Aug; 130(2):279-95. PubMed ID: 25920452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells.
    Haarmann A; Nehen M; Deiß A; Buttmann M
    Int J Mol Sci; 2015 Aug; 16(8):19086-95. PubMed ID: 26287168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.
    Montes Diaz G; Fraussen J; Van Wijmeersch B; Hupperts R; Somers V
    Sci Rep; 2018 May; 8(1):8194. PubMed ID: 29844361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.